Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) announced its quarterly earnings data on Friday. The company reported $999.00 EPS for the quarter, Zacks reports.
Appili Therapeutics Stock Performance
Appili Therapeutics stock remained flat at $0.01 during midday trading on Friday. The company had a trading volume of 61,946 shares, compared to its average volume of 8,845. The firm has a 50 day moving average price of $0.01 and a 200-day moving average price of $0.01. The company has a market cap of $1.50 million, a price-to-earnings ratio of -0.38 and a beta of -0.06. Appili Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.03.
Appili Therapeutics Company Profile
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Recommended Stories
- Five stocks we like better than Appili Therapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
